

NIH funding opportunities

25 August 2024 (#24)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-OD-24-163](#) NIH's Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by **May 25, 2025 for **Applications** and **Research Performance Progress Reports (RPPRs)**. The Common Forms represent a collaborative effort between federal research agencies to ensure standard disclosure requirements. In accordance with NIH's Peer Review Regulations at [42 Code of Federal Regulations Part 52h](#), NIH currently plans to continue collecting three required agency specific data elements (i.e., Personal Statement, Contributions to Science, and Honors) to assess qualifications. **These data elements will be collected separately from the Common Forms on a new NIH Biographical Sketch Supplement.****

Biographical Sketch

- NIH will no longer accept the NIH Biographical Sketch format page.
- NIH will require the use of the Common Form for Biographical Sketch.
- NIH will require the use of a new NIH Biographical Sketch Supplement to collect the "Personal Statement," "Contributions to Science," and "Honors" statements.
- All Biosketches must be prepared on <https://www.ncbi.nlm.nih.gov/sciencv/>

Current and Pending (Other) Support

- NIH will no longer accept the NIH Other Support format page.
- NIH will require the use of the Common Form for Current and Pending (Other) Support.

Failure to use the required forms or format pages may cause NIH to withdraw your application from consideration.

[NOT-OD-24-086](#) New NIH "FORMS-I" Grant Application Forms and Instructions Coming for Due Dates on or after **January 25, 2025. All active [Parent](#) and IC-issued NOFOs with due dates on or after January 25, 2025, will be reissued or updated to add FORMS-I application packages.**

[NOT-OD-24-165](#) **Retirement of NIH's Automated Just-in-Time Email Notification.** This Guide Notice informs the extramural research community that the eRA system-generated email notification announcing the availability to submit Just-in-Time information for an application in eRA Commons will be retired as of October 1, 2024. This change has no impact on an applicant's ability to submit Just-in-Time information upon request from staff at the awarding institute or center. Official notification of the need for JIT material(s) will continue to be sent directly by NIH staff from the awarding Institute/Center to those who are required to provide the material(s).

[NOT-TW-24-009](#) **Notice of NIH Participation in the Ecology and Evolution of Infectious Diseases Program.** The purpose of this Notice is to announce that the NIH is collaborating on the multi-agency funding opportunity, the Ecology and Evolution of Infectious Diseases (EEID) ([NSF 24-592](#)). **See below "Other Funding Opportunities".** The Fogarty International Center ([FIC](#)), the National Institute of Allergy and Infectious Diseases ([NIAID](#)) and the National Institute of General Medical Sciences ([NIGMS](#)) of the National Institutes of Health (NIH), the United States Department of Agriculture ([USDA](#)), and the National Science Foundation ([NSF](#)) will continue this multi-year collaboration that supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The FIC is interested in EEID applications that include explicit plans for capacity building in [Low- or Middle-Income Countries \(LMICs\), as defined by the World Bank](#) and encourages applications that are focused on significant and/or emerging infectious disease threats, including zoonotic disease threats, to human health in LMICs. To be considered for FIC support, EEID applications must be submitted by LMIC applicants or must demonstrate equitable LMIC research collaboration with LMIC investigator(s) in a leadership role on the proposed research if submitted by US applicants. The FIC will consider supporting meritorious EEID research applications that address the above priorities and/or meritorious EEID Research Coordination Network (RCN) applications aimed at capacity building in LMICs. **For awards made by components of the NIH, requested budgets should not exceed \$350,000 in direct costs per year for up to five years. The NIH will consider both EEID research applications and Research Coordination Network (RCN) applications. The deadline for submission to NSF is November 20, 2024. In subsequent years, the deadline is the third Wednesday in November.**

Parent Announcements

[NOT-OD-24-099](#) **Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates **Modified Expiration Date: January 8, 2025**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

[NOT-CA-24-074](#) **Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research.** This NOSI is to support applications improving diet and/or physical activity assessment biomarker development for evaluating lifestyle-based cancer prevention and interception approaches across diverse settings. Preclinical and pilot human studies assessing baseline and recovery biomarkers for dietary intake, nutritional status, and/or physical activity intervention(s) as complementary exposures are important for early cancer prevention and its interception in high-risk individuals or groups. This Notice applies to due dates on or after October 5, 2024, and subsequent application due dates through January 08, 2027.

[NOT-DA-26-008](#) **Research on Illicit Drug Markets.** The purpose of this NOSI is to encourage research that examines illicit drug markets and informs prevention, intervention, treatment, and harm reduction efforts. This NOSI's primary

interest is U.S. illicit drug markets; however, research involving international illicit drug markets will be considered in the context of the impacts and influences they have on U.S. drug markets, drug use, or substance-related harms. This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 8, 2028.

[NOT-AT-24-041](#) Fundamental Science Research on Complementary and Integrative Health Approaches, Including Natural Products or Mind and Body Interventions. The purpose of this (NOS) is to describe National Center of Complementary and Integrative Health (NCCIH) priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches and their impact on health outcomes, resilience, and well-being. This notice applies to due dates on or after October 7, 2024 and subsequent receipt dates through October 18, 2027.

[NOT-HL-24-018](#) Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS). Individuals with Postural Orthostatic Tachycardia Syndrome (POTS) suffer from an excessive increase in heart rate (tachycardia) and other symptoms of dysautonomia that worsen upon standing or sitting up, such as light-headedness, shortness of breath, chest pain, and palpitations. POTS is a debilitating condition that affects between 0.2 and 1% of the US population and may be even more prevalent since the COVID-19 pandemic and is often co-morbid in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. The condition impairs individuals' ability to participate in routine activities such as working, attending school, exercising and activities of daily life. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. Applicants must select the IC and associated NOFO to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that NOFO. This notice applies to due dates on or after October 05, 2024, and subsequent receipt dates through January 7, 2028.

Notice of Funding Opportunity (NOFO)

[RFA-AG-25-022](#) Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed). The purpose of this NOFO is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for AD/ADRD.

Dates: November 01, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: Anticipated Number of Awards: Up to 6 awards. Application budgets are limited to \$500,000 in direct costs per year and should reflect the actual needs of the proposed project. The maximum project period is five years.

[RFA-AG-25-023](#) Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed). The purpose of this NOFO is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports exploratory and developmental grant (R21) applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications.

Dates: November 01, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: Anticipated Number of Awards: Up to 5 awards. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

[RFA-AI-24-071](#) Promoting Innovative Research in *Treponema pallidum* Pathogenesis (R21 Clinical Trial Not Allowed). The purpose of this NOFO is to support basic and exploratory research projects to advance our understanding of *Treponema pallidum* bacterial pathogenesis.

Dates: November 04, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date. All applications are due by 5:00 PM local time of applicant organization. **Letter of Intent** due 30 days prior to the application due date.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

[RFA-DA-25-024 High Priority HIV and Substance Use Research \(R01 Clinical Trial Optional\)](#). The purpose of this NOFO is to support high priority research at the intersection of HIV and substance use. This NOFO invites research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use addictive substances. Applications submitted under this NOFO are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This initiative is open to both individual researchers and research teams. It addresses basic science, epidemiologic, clinical, intervention, and implementation research related to HIV in people with substance use and substance use disorders (SUDs). The proposed research areas must align with the NIH's HIV/AIDS Research Priorities: [NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Dates: February 11, 2025; August 13, 2025; February 11, 2026; August 13, 2026; February 11, 2027. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NIDA intends to commit \$3.0 M in FY 2025, 2026, and 2027 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

[RFA-DA-25-063 Microglial Pathophysiology in Comorbid Substance Use Disorder \(SUD\) and HIV \(R61/R33 Clinical Trial Not Allowed\)](#). The purpose of this notice of funding opportunity (NOFO) is to seek applications that examine protein interaction networks in HIV-infected microglia, and how these host-viral interactions contribute to cell type- and brain region-specific alterations in cellular signaling in the context of comorbid HIV and substance use disorder (SUD).

Date: August 14, 2025. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NIDA intends to commit \$2.5M in FY 2026 to fund 3-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Projects proposed may not exceed five years of total effort.

[PAR-24-269 National Institute on Drug Abuse \(NIDA\) Animal Genomics Program \(U01 – Clinical Trial Not Allowed\)](#). The purpose of the National Institute on Drug Abuse (NIDA) Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie neural and behavioral processes and phenotypes relevant to SUD risk, the SUD trajectory and SUD comorbidities. This opportunity supports research that links genetic, genomic and molecular mechanisms to neural circuit function and behavior. Applications may seek to identify any type of genomic and/or epigenomic variants that contribute to the genetic architecture of addiction, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, data-based, and/or artificial intelligence/machine learning approaches that integrate multi-level 'omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include variant identification at the circuit level and the application of neuroscience to variant identification studies in tissues and cells. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.

Date: February 11, 2025; July 23, 2025; February 11, 2026; July 23, 2026; February 11, 2027. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

[RFA-AG-25-026 Investigating Mitochondrial-Nuclear Communication in AD/ADRD \(R01 Clinical Trial Not Allowed\)](#). This Notice of Funding Opportunity (NOFO) invites R01 applications that investigate mitochondrial-nuclear communication in the context of neurobiology and Alzheimer's disease (AD) and AD-related dementias (AD/ADRD). This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. This has the potential to serve as the foundation for the development of future AD/ADRD therapies that specifically target mitochondrial function as well as shed light on the role that mitochondria play in aging and neurodegeneration.

Date: November 07, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NIA intends to commit \$4M in FY 2025 to fund eight awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed five years.

[RFA-CA-25-011](#) The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional). Through this notice of funding opportunity (NOFO) as a request for applications (RFA), the National Cancer Institute (NCI) intends to support research that expands the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes research in domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated.

Date: December 10, 2024. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NCI intends to commit \$5 million total in FY 2025 to fund up to 6 awards. Direct costs in any single year should reflect the actual needs of the proposed project; however, budgets are limited to \$500,000 Direct Costs (excluding consortium F&A) per year. The maximum project period is 5 years.

[RFA-DA-26-001](#) Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed). The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) and Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.

Dates: March 19, 2025; March 19, 2026. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NIDA intends to commit \$3M in FY2026 and FY2027 to fund a total of six to seven R01 or R21 projects each funding year from this NOFO and its companion [RFA-DA-26-002](#). Application budgets for the R01 are limited to \$350K direct costs and need to reflect the actual needs of the proposed project.

[RFA-DA-26-007](#) Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed). The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorder (SUD) comorbidity. This NOFO uses the R01 grant mechanism, while [RFA-DA-26-008](#) uses the R21 mechanism. Applicants with preliminary data may wish to apply to this R01 NOFO. High risk high reward projects that lack preliminary data may be most appropriate for the companion R21 NOFO.

Date: March 13, 2025. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Budget: NIDA intends to commit \$3,000,000 in FY 2026 to fund four-six projects from this and the companion NOFO [RFA-DA-26-008](#). Application budgets for the R01 are limited to \$400,000 in direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

[RFA-FD-25-001](#) Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required. The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.

Dates: October 22, 2024, by 11:59 PM Eastern Time; October 21, 2025, by 11:59 PM Eastern Time.

Budget: Award(s) will provide one (1) year of support and include future recommended support for an additional three (3) years contingent upon annual appropriations, availability of funding, and satisfactory recipient performance. YR 01: \$650,000; YR 02: \$650,000; YR 03: \$650,000; YR 04: \$650,000. Applicants may request additional funding over the above listed maximums for innovative and efficient trial approaches. The additional funding request shall not exceed

an additional \$250,000 total costs per year (to a maximum total award cost of \$900,000 per year) for up to 4 years. Justification for the additional funding request must be reflected in the budget request and will be reviewed annually by the program. The scope of the proposed project should determine the project period. The maximum project period is four (4) years; however, the length of support will depend on the nature of the study.

Other Funding Opportunities

US National Science Foundation NSF 24-592: Ecology and Evolution of Infectious Diseases (EEID). The goal of the Ecology and Evolution of Infectious Diseases (EEID) program is to support important and innovative research on the ecological, evolutionary, behavioral, physiological, oceanographic, and socio-ecological principles that influence the transmission dynamics of infectious diseases. The program's focus is on the discovery of general principles and processes and on building and testing models that elucidate these principles. Projects must address the quantitative, mathematical, or computational understanding of pathogen transmission dynamics

Dates: November 20, 2024. Annually Thereafter. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent due 30 days prior to the application due date.

Institutions eligible for awards by the NIH's Fogarty International Center include foreign institutions in [low- and middle-income countries \(LMICs\), as defined by the World Bank](#) (foreign institutions in high-income countries are not eligible for FIC awards).

Budget: EEID projects must have a minimum budget of \$1,500,000 in total project costs for all years, except that International Collaborative Proposals must have a minimum US budget of \$1,000,000 in total project costs for all years. Research that falls within the scope of the EEID initiative but with project aims that do not require budgets of this magnitude should be directed to the appropriate NSF core program. It is anticipated the EEID program will issue approximately ten awards (through all EEID partners combined) in Fiscal Year 2025 for projects to begin in the summer of 2025, subject to the availability of funds. **For awards made by components of the NIH, requested budgets should not exceed \$350,000 in direct costs per year for up to five years. The NIH will consider both EEID research applications and Research Coordination Network (RCN) applications.**

Faculty of Medicine and Health Sciences
Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)
009 Kth Floor, Teaching Block, Tygerberg Campus.

Enquiries: fmhsgmo@sun.ac.za

Add "Interest in NIH opportunity" in the subject line.

Add the notice number with hyperlink in the text of the email.